Life and death in the trash heap: The ubiquitin proteasome pathway and UCHL1 in brain aging, neurodegenerative disease and cerebral Ischemia
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The ubiquitin proteasome pathway (UPP) is essential for removing abnormal proteins and preventing accumulation of potentially toxic proteins within the neuron. UPP dysfunction occurs with normal aging and is associated with abnormal accumulation of protein aggregates within neurons in neurodegenerative diseases. Ischemia disrupts UPP function and thus may contribute to UPP dysfunction seen in the aging brain and in neurodegenerative diseases. Ubiquitin carboxy-terminal hydrolase L1 (UCHL1), an important component of the UPP in the neuron, is covalently modified and its activity inhibited by reactive lipids produced after ischemia. As a result, degradation of toxic proteins is impaired which may exacerbate neuronal function and cell death in stroke and neurodegenerative diseases. Preserving or restoring UCHL1 activity may be an effective therapeutic strategy in stroke and neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 3×
“These toxins include abnormally folded or aggregated proteins (Haass and Selkoe, 2007).”
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“In turn, impaired proteasome activity may account for decreased clearance of both hyperphosphorylated tau and Asheets (Mawuenyega et al., 2010; Sulistio and Heese, 2016).”
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024 · cited 1×
“Parkin (PARK2), another gene mutated in familial PD, is an E3-ubiquitin ligase, which plays an important role in selecting proteins for ubiquitination (Imai et al., 2001; Shimura et al., 2000; Zhang et al., 2000).”
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992 · cited 1×
“In addition to infarctions, small vessel disease may also result in oligemia: less severe hypoperfusion that results in mild ischemia but not cell death and infarction (Iadecola, 2003; Koike et al., 2010; Saito and Ihara, 2016; Schneider et al., 2007; Shang et al., 2016) .”
Goedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.242 · Cited by 1,190
Zhang, Y., Gao, J., Chung, K. K. K., Huang, H., Dawson, V. L., & Dawson, T. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.240347797 · Cited by 982
Degradation of misfolded proteins in neurodegenerative diseases: Therapeutic targets and strategies
Ciechanover, A., & Kwon, Y. T. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.117 · Cited by 898
The emerging complexity of protein ubiquitination
Komander, D. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370937 · Cited by 821
Tau protein pathology in neurodegenerative diseases
Spillantini, M. G., & Goedert, M. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01337-x · Cited by 683
Choi, J., Levey, A. I., Weintraub, S. T., Rees, H. D., Gearing, M., Chin, L.-S., & Li, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314124200 · Cited by 568 · cited 10×
“The aggregates also contain proteasome components and cytoskeletal elements associated with the UPP and are termed aggresomes (Choi et al., 2004).”
InfluentialNeurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease
Nelson, A. R., Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.12.016 · Cited by 559
Proteasome inhibition by paired helical filament‐tau in brains of patients with Alzheimer's disease
Keck, S., Nitsch, R., Grune, T., & Ullrich, O. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01642.x · Cited by 483
Phosphorylated α-Synuclein Is Ubiquitinated in α-Synucleinopathy Lesions
Hasegawa, M., Fujiwara, H., Nonaka, T., Wakabayashi, K., Takahashi, H., Lee, V. M.-Y., Trojanowski, J. Q., Mann, D., & Iwatsubo, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208046200 · Cited by 428 · cited 1×
“Many of these proteins are ubiquitinated suggesting that they were destined for degradation via the UPP (Hasegawa et al., 2002; McNaught et al., 2001; Moore et al., 2003).”
Aβ inhibits the proteasome and enhances amyloid and tau accumulation
Tseng, B. P., Green, K. N., Chan, J. L., Blurton-Jones, M., & LaFerla, F. M. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.014 · Cited by 384
Decreased levels of proteasome activity and proteasome expression in aging spinal cord
Keller, J. N., Huang, F. F., & Markesbery, W. R. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00067-1 · Cited by 297
Kabuta, T., Furuta, A., Aoki, S., Furuta, K., & Wada, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801918200 · Cited by 227
Tashiro, Y., Urushitani, M., Inoue, H., Koike, M., Uchiyama, Y., Komatsu, M., Tanaka, K., Yamazaki, M., Abe, M., Misawa, H., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.417600 · Cited by 194 · cited 2×
“accumulated in motor neurons, together with other typical ALS hallmarks such as basophilic inclusion bodies(Tashiro et al., 2012).”
Oligemic Hypoperfusion Differentially Affects Tau and Amyloid-β
Koike, M. A., Green, K. N., Blurton-Jones, M., & LaFerla, F. M. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090750 · Cited by 130
The ubiquitin proteasome system in synaptic and axonal degeneration
Korhonen, L., & Lindholm, D. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200311091 · Cited by 72
The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration
Deger, J. M., Gerson, J. E., & Kayed, R. (2015) · Aging Cell · doi:10.1111/acel.12359 · Cited by 69 · cited 1×
“A oligomers accumulate within neurons and there are extracellular accumulations of high molecular weight deposits of A peptides in the fibular form (Deger et al., 2015; Gadhave et al., 2016).”
Interaction between cerebrovascular disease and Alzheimer pathology
Saito, S., & Ihara, M. (2016) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000239 · Cited by 69
Cited by
Hallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States
Mattson, M. P., & Arumugam, T. V. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.011 · Cited by 1,242
Molecular basis of GID4-mediated recognition of degrons for the Pro/N-end rule pathway
Dong, C., Zhang, H., Li, L., Tempel, W., Loppnau, P., & Min, J. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0036-1 · Cited by 111
Scudder, S. L., Gonzales, F. R., Howell, K. K., Stein, I. S., Dozier, L. E., Anagnostaras, S. G., Zito, K., & Patrick, G. N. (2021) · eNeuro · doi:10.1523/eneuro.0073-20.2021 · Cited by 10
Metadata
- Authors
- Graham, S. H., & Liu, H.
- Venue
- Ageing Research Reviews
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 34
- Pages
- 30-38
- ISSN
- 1568-1637 (ISSN-L)
- OpenAlex
- W2529372108
- Cited by
- 94
- References
- 22
- FWCI
- 0.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.